Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity Before and After Neoadjuvant Chemotherapy

Cancers - Switzerland
doi 10.3390/cancers11111753
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

CD44v9 as a Poor Prognostic Factor of Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2018English

Targeted Therapies in Triple-Negative Breast Cancer: Failure and Future

Women's Health
Medicine
2015English

Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Dasatinib Sensitises Triple Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells

British Journal of Cancer
Cancer ResearchOncology
2018English

Patterns of Dual-Specific Phosphatase 4 mRNA Expression Before and After Neoadjuvant Chemotherapy in Breast Cancer

Asian Pacific Journal of Cancer Prevention
2019English

Neutrophil–lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer

Current Oncology
Oncology
2018English

Ki67 Measured After Neoadjuvant Chemotherapy for Primary Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy